The Arrival of Actionable Personalized Medicine

The pace of implementation of next-generation sequencing (NGS) in a clinical context, which almost rivals the development of the technology over the past decade, is driving the cost of a full genome sequence down to just a few thousand dollars. Diagnostic companies and medical centers are now routinely offering comprehensive genome analysis, as evidenced by the recent report from Baylor College of Medicine in the New England Journal of Medicine on the first 250 patients studied using whole-exome sequencing.

Companies such as Foundation Medicine, Courtagen and InVitae are targeting large panels of genes to tackle cancer, mitochondrial disorders and Mendelian disease. Meanwhile, the community is actively debating the best methods for communicating secondary findings to patients and their families.

This is among the exciting topics that will be addressed at the 7th Annual Personalized Medicine World Conference on January 27 and 28 in Silicon Valley will feature world-renowned experts engaged in developing and implementing advances in clinical molecular diagnostics and personalized medicine.

The theme of the 2014 conference is: The Arrival of Actionable Personalized Medicine: The Age of Guided Disease Management. The meeting will begin with discussions featuring a host of luminaries from the field of personalized medicine, including Brook Byers, Randy Scott, Lee Hood, and NHGRI director Eric Green. There will be lively discussion of major issues including the impact of the Supreme Court’s gene patent decision, the development of targeted therapies in cancer and neurological disorders, as well as regulatory and reimbursement trends.

PMWC 2014 is proud to honor Jay Flatley, CEO of Illumina, at the 2014 conference, for building the world’s premier genome analysis platforms. Since the acquisition of the British biotech company Solexa in 2007, Illumina has been a dominant leader in NGS technology. But the field is poised for another technological surge as exciting new technologies, notably nanopore sequencing, are on the verge of being commercialized.

A panel discussion – “Killer apps, genome interpretation and the future of NGS” – will feature four leaders in DNA sequencing and  chart the future growth of the field. The panelists include Stanford University’s Steve Quake, the co-founder of Fluidigm and Helicos; Michael Hunkapiller, chief executive of Pacific Biosciences (and formerly of Applied Biosystems); Cliff Reid, the founding CEO of Complete Genomics, now part of BGI; and Stefan Roever, CEO of nanopore sequencing start-up Genia Technologies. Will anyone succeed in knocking Flatley and Illumina off their perch? Come to PMWC 2014 and find out!

We hope you will be able to join us!
http://2014sv.pmwcintl.com/

Kevin Davies PhD is the author of “The $1,000 Genome” and “Cracking the Genome.” He is the founding editor of Nature Genetics and the launch editor of Bio-IT World magazine. Kevin recently took up a new publishing role with the American Chemical Society. He is also collaborating with one James D. Watson on a new edition of the book “DNA”.

Health  |  Email This Post  |  Printer Friendly
Tags: , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>